1. Date of occurrence of the event:2016/09/23
2. Company name: OBI Pharma, Inc.
3. Relationship to the Company (please enter ”head office” or ”affiliatecompany”): N/A
4. Reciprocal shareholding ratios: N/A
5. Name of mass media: Page C6 of Economic Daily News
6. Content reported: The progress of OBI Pharma (4174)’s breast cancer new drug OBI-822 is likely to be
faster than expected. According to an authoritative person(s), OBI is likely to complete the US Phase
III trial design in October this year, and discuss about the trail details and feasibility with the FDA, bringing new possibilities to the drug development of the company.
7. Cause of occurrence: To clarify report on page C6 of Economic Daily News
8.Countermeasures: OBI continuously devote in designing the OBI-822 Phase III clinical trial. There is no
clear timeline. If there is any major advance, the company will definitely announce. The company did not
comment about the above news.
9. Any other matters that need to be specified: The results of a single clinical trial are not enough to
fully reflect the success or failure of future development of new drugs listed, and the investors should
carefully make the judgement and be prudent in their investment.For the new drugs, the development
process is long, the expense is high and its success cannot be guaranteed. All these factors might make
the investment risky, the investors should carefully make their call and be prudent in the investment.